Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | March 31, 2021 | April 02, 2021 |
| GeoVax Labs, Inc.GOVX · Entity 8419 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date March 31, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,361 |
Reported balance
After 2021-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-31 · Grant · Acquired 319 · Balance 24,361 F1: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. F2: Includes 23,219 shares held jointly with spouse and 510 shares held in an IRA. |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter's IRA | 187 |
Reported balance
Holding disclosure · report date 2021-03-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 187 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021.
F2: Includes 23,219 shares held jointly with spouse and 510 shares held in an IRA.
GeoVax Labs, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-06-17 | Direct | 6,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 6,000 · Balance 6,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:22 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021323 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 13:11 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock | 10,000 | $0.55 | $5,498.00 |
DisclosureSEC source: 0001437749-25-031314 · rdgdoc.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,402 Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:45 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019634 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 17:23 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock | 10,000 | $0.98 | $9,800.00 |
DisclosureSEC source: 0001437749-25-011750 · rdgdoc.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,402 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:06 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026786 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 01, 2023 Filed Aug 14, 2023 20:53 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023746 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 22:24 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001437749-21-028134 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-07 Read SEC document |
| August 11, 2021 Filed Aug 11, 2021 21:31 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001437749-21-019503 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-02 F1 · date: This stock option was granted on December 2, 2020, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval was obtained on August 11, 2021, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F2 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 319 | $19.57 | $6,242.83 |
DisclosureSEC source: 0001420506-21-000377 · doc4_919.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,361 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. F2 · ownership.direct: Includes 23,219 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 23:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 208 | $15.00 | $3,120.00 |
DisclosureSEC source: 0001420506-21-000007 · doc4_891.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,042 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. F2 · ownership.direct: Includes 22,900 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:09 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 547 | $5.71 | $3,123.37 |
DisclosureSEC source: 0001420506-20-001035 · doc4_861.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,834 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. F2 · ownership.direct: Includes 22,692 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 22:27 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock Purchase Warrant · Derivative | 21,024 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001437749-20-020451 · rdgdoc.xml · derivative · entry 2 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,024 Underlying: Common Stock · 21,024 shares Expires 2025-09-29 F1 · derivative.exercise_date: These securities are subject to a lock-up agreement, dated August 31, 2020, between the Reporting Person and Maxim Group LLC. The securities may not be sold, exercised, or otherwise transferred prior to March 29, 2021, unless the restrictions are earlier waived by Maxim Group LLC or pursuant to specific exemptions in the lock-up agreement. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 22:27 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | PurchaseCommon Stock | 21,024 | $5.00 | $105,120.00 |
DisclosureSEC source: 0001437749-20-020451 · rdgdoc.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,024 F1 · balance_after: These securities are subject to a lock-up agreement, dated August 31, 2020, between the Reporting Person and Maxim Group LLC. The securities may not be sold, exercised, or otherwise transferred prior to March 29, 2021, unless the restrictions are earlier waived by Maxim Group LLC or pursuant to specific exemptions in the lock-up agreement. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:56 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 879 | $3.55 | $3,120.45 |
DisclosureSEC source: 0001171520-20-000282 · doc4_821.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,287 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. F2 · ownership.direct: Includes 22,145 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 20:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000691 · doc4_812.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 875 | $3.57 | $3,123.75 |
DisclosureSEC source: 0001420506-20-000356 · doc4_798.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,408 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020. F2 · ownership.direct: Includes 21,266 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:06 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 630 | $4.96 | $3,124.80 |
DisclosureSEC source: 0001420506-20-000011 · doc4_784.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,533 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. F2 · ownership.direct: Includes 20,391 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:13 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 667 | $5.15 | $3,435.05 |
DisclosureSEC source: 0001534424-19-000274 · ownership.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,903 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019. F2 · ownership.direct: Includes 19,761 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:13 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,085 | $3.17 | $3,439.45 |
DisclosureSEC source: 0001534424-19-000200 · ownership.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,236 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019. F2 · ownership.direct: Includes 19,094 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001534424-19-000177 · ownership.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,092 | $3.15 | $3,439.80 |
DisclosureSEC source: 0001534424-19-000098 · ownership.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,151 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019. F2 · ownership.direct: Includes 18,009 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:06 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,338 | $1.47 | $3,436.86 |
DisclosureSEC source: 0001534424-19-000009 · ownership.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,059 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018. F2 · ownership.direct: Includes 16,917 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:39 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 345,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001437749-18-022299 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 345,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:46 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,956 | $1.76 | $3,442.56 |
DisclosureSEC source: 0001534424-18-000339 · ownership.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,721 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018. F2 · ownership.direct: Includes 14,579 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:10 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,578 | $2.18 | $3,440.04 |
DisclosureSEC source: 0001534424-18-000242 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,765 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018. F2 · ownership.direct: Includes 12,623 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 12:55 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001534424-18-000210 · spencer.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 21:00 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,097 | $3.13 | $3,433.61 |
DisclosureSEC source: 0001534424-18-000115 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,187 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. F2 · ownership.direct: Includes 11,045 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 29, 2017 Filed Jan 26, 2018 21:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,940 | $2.75 | $5,335.00 |
DisclosureSEC source: 0001534424-18-000029 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,090 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.75 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 29, 2017. F2 · ownership.direct: Includes 9,948 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:25 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 240,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001437749-17-021100 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2027-12-20 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:26 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000503 · spencer.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:15 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,022 | $2.47 | $4,994.34 |
DisclosureSEC source: 0001534424-17-000417 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,150 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017. F2 · ownership.direct: Includes 8,008 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 21:49 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,896 | $2.64 | $5,005.44 |
DisclosureSEC source: 0001534424-17-000011 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,128 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $2.64 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 30, 2016. F2 · ownership.direct: Includes 5,986 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 21:37 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 123,500 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001437749-16-043432 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,500 Underlying: Common Stock · 123,500 shares Expires 2026-12-13 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:37 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 701 | $6.65 | $4,661.65 |
DisclosureSEC source: 0001534424-16-001073 · spencer.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,232 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $6.65 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2016. F2 · ownership.direct: Includes 4,090 shares held jointly with spouse and 510 shares held in an IRA. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.